ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "morbidity and mortality"

  • Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting

    Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study

    Ju Ann1, Hyon K. Choi2, Sharan K. Rai3, Eric C. Sayre4 and J Antonio Avina-Zubieta5,6, 1Experimental Mediine, University of British Columbia, Richmond, BC, Canada, 2Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada, Richmond, BC, Canada, 5Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, 6Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada

    Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
  • Abstract Number: 909 • 2015 ACR/ARHP Annual Meeting

    Smoking Behavior Changes after Rheumatoid Arthritis Diagnosis and Risk of Mortality during 36 Years of Prospective Follow-up

    Jeffrey A. Sparks1, Uyen Sa D.T. Nguyen2,3, Shun-Chiao Chang4,5, Yuqing Zhang6, Hyon Choi7 and Elizabeth W. Karlson4, 1Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, 3Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 7Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Smoking is a major preventable cause of death and cessation is recommended for the general population. However, it is unclear whether being diagnosis with…
  • Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting

    Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis

    Ängla Mantel1, Marie Holmqvist1, Tomas Jernberg2, Solveig Wållberg-Jonsson3 and Johan Askling4,5, 1Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, 3Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, 4Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…
  • Abstract Number: 985 • 2015 ACR/ARHP Annual Meeting

    Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study

    Kateryna Vostretsova1, Sharan K. Rai2, Eric C. Sayre3, Hyon K. Choi4, JM Esdaile5 and J Antonio Avina-Zubieta6, 1Rheumatology, Arthritis Research Centre, Vancouver, BC, Canada, 2Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 6Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of mortality. However, recent mortality trends of SLE are unknown, particularly at the general…
  • Abstract Number: 2413 • 2015 ACR/ARHP Annual Meeting

    Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort

    Lauren King1, Tetyana Kendzerska1,2,3 and Gillian Hawker1,2,3, 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Osteoarthritis (OA) is associated with functional limitations, including difficulty walking. However, comorbid disease is common in people with OA and may also be associated…
  • Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting

    Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice

    Richard Bell1, Ronald Wood2, Joe Chakkalakal3, Christopher T. Ritchlin4, Edward Schwarz5 and Homaira Rahimi6, 1Pathology, University of Rochester, Rochester, NY, 2University of Rochester, Rochester, NY, 3Orthopaedics, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Orthopedeatrics, University of Rochester, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
  • Abstract Number: 3240 • 2015 ACR/ARHP Annual Meeting

    Improved Survival in Rheumatoid Arthritis: A General Population-Based Study

    Na Lu1,2, Hyon K. Choi3, Sara R. Schoenfeld3, Christine Peloquin4, Maureen Dubreuil5, Sharan K. Rai6, J Antonio Avina-Zubieta7 and Yuqing Zhang8, 1Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 5Rheumatology, Boston VA HealthCare System, Boston, MA, 6Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 7Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, 8BUSM, Boston, MA

    Background/Purpose: All-cause mortality in UK has been decline by almost 20% over the past two decades. While rheumatoid arthritis (RA) is associated with an increased…
  • Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting

    Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010

    Eric Y Yen1, Magda Shaheen2, Jennifer MP Woo3, Deborah K. McCurdy4 and Ram Raj Singh5, 1Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2Charles R. Drew University of Medicine and Science, Los Angeles, CA, 3UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 4Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 5Medicine, UCLA Division of Rheumatology, Los Angeles, CA

    Title:  Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose:  Many epidemiologic studies of systemic…
  • Abstract Number: 817 • 2014 ACR/ARHP Annual Meeting

    Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years

    I.M. Markusse1, L. Dirven2, J.H. van Groenendael3, K.H. Han4, H.K Ronday5, P.J.S.M. Kerstens6, W.F. Lems7,8, T.W.J. Huizinga2 and C.F. Allaart2, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Fransiscus Hospital, Roosendaal, Netherlands, 4Rheumatology, MCRZ hospital, Rotterdam, Netherlands, 5Rheumatology, Haga Hospital, The Hague, Netherlands, 6Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 7Rheumatology, VU Medical Center, Amsterdam, Netherlands, 8Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of…
  • Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting

    Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients

    Anna-Maria Hoffmann-Vold1, Oyvind Midtvedt2, Torhild Garen3, May Brit Lund4, T. Mogens Aalokken5, Jan Tore Gran2 and Oyvind Molberg6, 1Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Rheumatology, Oslo University Hospital, Oslo, Norway, 3Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 4Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, 5Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 6Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…
  • Abstract Number: 2997 • 2014 ACR/ARHP Annual Meeting

    Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients

    Robyn T. Domsic1, Svetlana I. Nihtyanova2, Mary Lucas3, Stephen R. Wisniewski4, Michael J. Fine5, C. Kent Kwoh6, Christopher P. Denton7 and Thomas A. Medsger Jr.8, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 3Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 5General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 61501 N. Campbell Avenue, Room 8303, The University of Arizona Arthritis Center, Tucson, AZ, 7Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 8Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose : Knowledge of mortality risk and predictors is important in systemic sclerosis (SSc) patient care and clinical trial design.   There is no validated 5-year…
  • Abstract Number: 3000 • 2014 ACR/ARHP Annual Meeting

    Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity

    Hebah Alhajeri1, Marie Hudson2,3, Canadian Scleroderma Research Group CSRG4 and Murray Baron5, 1Rheumatology, McGill University, Montreal, QC, Canada, 2Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Division of Rheumatology, McGill University, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Identifying systemic sclerosis (SSc) subsets that predict mortality and morbidity could provide useful prognostic information. We undertook this study to compare the predictive ability…
  • Abstract Number: 2941 • 2014 ACR/ARHP Annual Meeting

    Physical Function Is Independently Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project

    Rebecca J. Cleveland1, Todd Schwartz1, Jordan B. Renner2, Joanne M. Jordan3 and Leigh F. Callahan4, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina Department of Radiology, Chapel Hill, NC, 3University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC

    Background/Purpose Declining physical function (PF) is a common consequence of osteoarthritis (OA), and poor PF is associated with death. It is possible that the resulting…
  • Abstract Number: 2620 • 2014 ACR/ARHP Annual Meeting

    Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to 2013

    Sergi Heredia1, Javier Narváez2, Andrea Zacarias1, Milagros Ricse1, Gloria Albert1, Eulalia Armengol1, Helena Borrell1, Olga Capdevila3, Francesca Mitjavila3, Toni Rozadilla1, Xavier Juanola4 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 3Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Rheumatology, University Hospital Bellvitge, Barcelona, Spain

    Background/Purpose: To study the mortality, survival and causes of death in a Spanish cohort of patients with systemic lupus erythematosus (SLE) over a 28-year period…
  • Abstract Number: 2188 • 2014 ACR/ARHP Annual Meeting

    Incidence and Mortality of Relapsing Polychondritis in the United Kingdom: A Population-Based Cohort Study

    Nisha Hazra1, Alex Dregan1, Judith Charlton1, Martin C Gulliford1 and David P. D'Cruz2, 1Division of Primary Care and Public Health Research, King's College London, London, United Kingdom, 2Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom

    Background/Purpose: To estimate the incidence, prevalence and mortality of Relapsing Polychondritis (RP), and to describe the clinical features of RP, in a large population.  Methods:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology